{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T18:50:22Z","timestamp":1672599022240},"reference-count":0,"publisher":"American Physiological Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Physiology-Endocrinology and Metabolism"],"published-print":{"date-parts":[[1995,12,1]]},"abstract":"<jats:p> In 28 adult Ins-IFN-gamma transgenic mice, injection of high doses of streptozotocin (STZ; first injection, 300 microgram\/g body weight; second injection, 200 microgram\/g body weight 4 h later) failed to induce severe hyperglycemia. To the contrary, 28 BALB\/c mice developed diabetes mellitus after identical injections of STZ. Because the STZ-induced islet damage was partially inhibited in Ins-IFN-gamma transgenic mice, their glycemia levels became normal 4 days after STZ administration. Both transgenic and BALB\/c mice lost weight after receiving STZ, but the body weights of transgenic mice then returned to pretreatment levels in a nearly parallel manner with the glycemia. Immunolabeling with insulin identified an unusual spreading pattern of insulin immunoreactivity. Ultrastructural observations confirmed that beta-cell necrosis and degranulation were more severe in STZ-treated BALB\/c than in Ins-IFN-gamma transgenic mice. Moreover, regeneration of pancreatic duct cells and islet neogenesis were observed in the transgenic mice. Therefore, after STZ treatment, the Ins-IFN-gamma transgenic mice apparently were resistant to the induction of severe diabetes, whereas their BALB\/c age-matched counterparts succumbed to the disease. <\/jats:p>","DOI":"10.1152\/ajpendo.1995.269.6.e1089","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T09:24:05Z","timestamp":1513934645000},"page":"E1089-E1094","source":"Crossref","is-referenced-by-count":2,"title":["Transgenic mice expressing IFN-gamma in pancreatic beta-cells are resistant to streptozotocin-induced diabetes"],"prefix":"10.1152","volume":"269","author":[{"given":"D.","family":"Gu","sequence":"first","affiliation":[{"name":"Department of Neuropharmacology, Scripps Research Institute, La Jolla,California 92037, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Arnush","sequence":"additional","affiliation":[{"name":"Department of Neuropharmacology, Scripps Research Institute, La Jolla,California 92037, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. P.","family":"Sawyer","sequence":"additional","affiliation":[{"name":"Department of Neuropharmacology, Scripps Research Institute, La Jolla,California 92037, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Sarvetnick","sequence":"additional","affiliation":[{"name":"Department of Neuropharmacology, Scripps Research Institute, La Jolla,California 92037, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"24","container-title":["American Journal of Physiology-Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.physiology.org\/doi\/pdf\/10.1152\/ajpendo.1995.269.6.E1089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T17:43:56Z","timestamp":1567964636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.physiology.org\/doi\/10.1152\/ajpendo.1995.269.6.E1089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,12,1]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1995,12,1]]}},"alternative-id":["10.1152\/ajpendo.1995.269.6.E1089"],"URL":"https:\/\/doi.org\/10.1152\/ajpendo.1995.269.6.e1089","relation":{},"ISSN":["0193-1849","1522-1555"],"issn-type":[{"value":"0193-1849","type":"print"},{"value":"1522-1555","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,12,1]]}}}